The carbapenem inoculum effect provides insight into the molecular mechanisms underlying carbapenem resistance in *Enterobacterales*

Alexis Jaramillo Cartagena[1†], Kyra L. Taylor[1†], Joshua T. Smith[1], Abigail L. Manson[1], Virginia M. Pierce[2,3], Ashlee M. Earl[1], Roby P. Bhattacharyya[1,4,*]

[1]Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
[2]Microbiology Laboratory, Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA
[3]Department of Pathology and Clinical Laboratories, University of Michigan, Ann Arbor, MI 48109, USA
[4]Infectious Diseases Division, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
[†]These authors contributed equally to this work.

*Corresponding Author

Email: rbhatt@broadinstitute.org

Author Contributions:
Designed research: AJC, KLT, RPB
Performed research: AJC, KLT, RPB
Contributed new reagents/analytic tools: AJC, KLT, RPB, AME
Analyzed data: AJC, KLT, RPB, JTS, ALM, VMP, AME
Wrote the paper: AJC, KLT, RPB, JTS, ALM, VMP, AME

Classification: Biological Sciences / Microbiology

Keywords: Antibiotic resistance, carbapenemases, inoculum effect, bacterial genomics, clinical microbiology

Abstract

Carbapenem-resistant *Enterobacterales* (CRE) are important pathogens that can develop resistance via multiple molecular mechanisms, including hydrolysis or reduced antibiotic influx. Identifying these mechanisms can improve pathogen surveillance, infection control, and patient care. We investigated how resistance mechanisms influence the carbapenem inoculum effect (IE), a phenomenon where inoculum size affects antimicrobial susceptibility testing (AST). We demonstrated that seven different carbapenemases impart a meropenem IE in *Escherichia coli*. Across 110 clinical CRE isolates, the carbapenem IE strictly depended on resistance mechanism: all carbapenemase-producing CRE (CP-CRE) exhibited a strong IE, whereas porin-deficient CRE displayed none. Concerningly, 50% and 24% of CP-CRE isolates changed susceptibility classification to meropenem and ertapenem, respectively, across the allowable inoculum range in clinical guidelines. The meropenem IE, and the ratio of ertapenem to meropenem minimal inhibitory concentration (MIC) at standard inoculum, reliably identified CP-CRE. Understanding how resistance mechanisms affect AST could improve diagnosis and guide therapies for CRE infections.

47 **Main Text**

48

49 **Introduction**

50

51 Carbapenems are a crucial class of β-lactam antibiotics with a broad spectrum of activity (1) due
52 to their ability to withstand hydrolysis by many β-lactamases and their inhibition of cell wall
53 synthesis across many bacterial species (2). The emergence of carbapenem-resistant
54 *Enterobacterales* (CRE) poses a significant public health risk, with the US Centers for Disease
55 Control and Prevention (CDC) designating them as an "urgent threat" due to their extensive
56 drug resistance, high mortality rates, and treatment challenges (3, 4). The rapid global
57 emergence of CRE has created an urgent clinical and epidemiological need to better
58 understand, detect, and limit the spread of these pathogens (5).

59 CRE employ two major molecular mechanisms of carbapenem resistance: 1) expression
60 of carbapenemases, which efficiently hydrolyze carbapenems, or 2) disruption of porins, which
61 reduces influx of carbapenems into the periplasm where they act (6). This reduced periplasmic
62 influx can potentiate β-lactamases with weak carbapenemase activity such as AmpC, CTX-M,
63 SHV, TEM, or OXA-10, and together cause resistance (1, 7). Efflux pumps can also contribute
64 to carbapenem resistance, though their role has been better characterized in non-
65 *Enterobacterales* species like *Acinetobacter baumannii* and *Pseudomonas aeruginosa* (8, 9).
66 Carbapenemase-producing CRE (CP-CRE) are of particular epidemiological concern due to
67 their propensity to cause outbreaks (4, 10) and the risk of horizontal transfer of carbapenemase
68 genes (11–13). Porin deficient CRE (PD-CRE) often exhibit impaired fitness (14) compared to
69 CP-CRE because porins play important roles in nutrient import (15), osmotic homeostasis (14,
70 16), and membrane lipid asymmetry (17). Determining resistance mechanisms could lead to
71 better infection control measures, such as patient isolation to prevent CP-CRE spread in
72 hospitals (4, 13, 18). Some laboratories test for resistance mechanisms in CRE (19–21), but this

requires additional time, equipment, expertise, and expenses. Capitalizing on existing antimicrobial susceptibility testing (AST) workflows to predict CRE resistance mechanisms would represent a clinical advance.

Standardized AST methods and interpretive criteria are crucial to determine antimicrobial susceptibility of pathogens. Organizations like the Clinical and Laboratory Standards Institute (CLSI) classify pathogen susceptibility based on minimum inhibitory concentration (MIC) breakpoints (22–24) that are established and periodically revised (25) based on microbiological, pharmacokinetic-pharmacodynamic, and clinical data. While these breakpoints are intended to predict clinical response to therapy, not resistance mechanism, carbapenem MICs have been repurposed to prioritize isolates for molecular carbapenemase testing (22, 26). In the United States, only isolates that test phenotypically carbapenem resistant are typically tested for carbapenemases (22). Yet despite recently updated breakpoints (27), some carbapenemase producing isolates can still be misclassified as susceptible to carbapenems (28).

The inoculum effect (IE) is a phenomenon whereby the measured MIC varies depending on the precise bacterial inoculum used in AST assays, which can lead to susceptibility misclassification and treatment failures (29, 30). Multiple factors may contribute to the IE, including metabolic state of the bacteria (31), growth productivity (32), antibiotic-target ratio (33), heteroresistance frequency (34), target proteolysis (35), and production of enzymes that inactivate antibiotics (36–40). The IE is frequently observed for some antibiotic classes including β-lactams (41) but not commonly for others such as aminoglycosides. While importance of the IE in clinical infections remains uncertain (42, 43), it has important implications for diagnostic accuracy. To minimize the impact of the IE, CLSI recommends a standard inoculum of 5×10^5 colony forming units (CFU)/mL, with an acceptable range of 2×10^5 to 8×10^5 CFU/mL, for broth microdilution, the gold standard AST method (44). Even within this range, however,

98 carbapenem susceptibility classification of *Enterobacterales* isolates may change due to the IE,
99 underscoring the need for continued efforts to optimize AST methods (45).
100 Here, we sought to systematically investigate how different genotypes conferring
101 carbapenem resistance influence the IE and how understanding these relationships might be
102 leveraged to improve clinical AST. We found that expression of distinct carbapenemases was
103 sufficient to cause a marked meropenem IE in a laboratory strain of *Escherichia coli*. Further, in
104 a collection of 110 clinical CRE isolates across 12 species of *Enterobacterales* (11, 46), we
105 observed that the carbapenem IE was a function of resistance mechanism. Specifically, all CP-
106 CRE exhibited a strong carbapenem IE, whereas all PD-CRE exhibited constant carbapenem
107 MICs across a wide range of inocula. Isolates with both a carbapenemase and porin deficiency
108 generally exhibited an IE and higher MICs than strains with either mechanism alone. The
109 carbapenem MICs of CP-CRE varied considerably, with a large proportion changing AST
110 classification across the CLSI-acceptable inoculum range. Collectively, our results
111 demonstrated that the IE distinguished CRE by resistance mechanism, better than either
112 meropenem or ertapenem MIC alone. These findings suggested two phenotypic measures that
113 predict carbapenem resistance mechanisms better than the MIC cutoffs currently used to
114 prioritize molecular carbapenemase testing.
115
116 **Results**
117
118 **Carbapenemases belonging to all four Ambler classes impart an inoculum effect.**
119 Carbapenemases are commonly divided into four classes based on protein sequence and
120 enzymatic features (47, 48). To investigate if each carbapenemase class is sufficient to confer
121 an IE, we systematically cloned seven different carbapenemase genes, each with its native
122 promoter, into a low-copy pBAD33 plasmid (49): bla_{KPC-3} and bla_{SME-2} from Ambler class A;
123 bla_{IMP-4}, bla_{NDM-1}, and bla_{VIM-27} from class B; bla_{CMY-10} (50) from class C; and bla_{OXA-48} from class D

124 (Supplementary Table S1). We transformed each carbapenemase-encoding plasmid into *E. coli*
125 K-12 MG1655, a carbapenem-susceptible laboratory strain, then conducted meropenem broth
126 microdilution MIC assays across a broad range of inocula, comprising two-fold dilutions from 1.3
127 × 10^7 to 1.6 × 10^3 CFU/mL. As inoculum increased, all transformants showed a significant
128 increase in MIC, while the MIC of the empty vector control did not (Fig. 1*A*). Most transformants
129 had stable meropenem MICs from ~10^3 to ~10^4 CFU/mL, and all exhibited a strong linear
130 increase in MIC across the ~10^5 to ~10^7 CFU/mL inoculum range, which includes the
131 recommended inoculum range for clinical testing (Fig. 1*B*). In this strain background, NDM-1
132 (orange), SME-2 (pink), and IMP-4 (brown) imparted the highest levels of resistance, followed
133 by VIM-27 (yellow). KPC-3 (teal) conferred high-level resistance at high inocula, but within the
134 CLSI inoculum range (dashed lines in Fig. 1*B*) MICs remained within the intermediate
135 classification (>1 μg/mL and <4 μg/mL). OXA-48 (violet) and CMY-10 (green) conferred the
136 lowest meropenem MICs, which remained below 1 μg/mL until the highest inoculum tested and
137 well within the susceptible classification in the CLSI range.
138
139 **Inoculum effect of clinical CRE isolates depends on resistance mechanism.** After
140 establishing that all carbapenemases imparted an IE in *E. coli* K-12, we investigated the IE in
141 clinical isolates harboring carbapenemases, porin disruptions, or both. We analyzed 110 clinical
142 isolates comprising six genera and 12 species (Table S2), which we assigned to three groups
143 based on their genotypes: CP-CRE, PD-CRE, and CP-CRE with porin deficiency (Fig. 2 and
144 Supplementary Fig. S1, Table S2 and Table S3). We observed that all 36 CP-CRE harboring
145 carbapenemases from one of six major families (KPC, NDM, IMP, VIM, OXA-48, and SME)
146 displayed an IE similar to the *E. coli* K-12 carbapenemase transformants (Fig. 2*A* and
147 Supplementary Fig. S1*A*). In contrast, 47 PD-CRE exhibited a strikingly different pattern of
148 resistance, with nearly constant MICs across the tested inoculum range (Fig. 2*B* and
149 Supplementary Fig. S1*B*). Finally, the 27 isolates with both carbapenemase production and

150 porin deficiencies, which we termed “hyper-CRE”, exhibited an IE and higher-level resistance
151 than isolates containing only one mechanism of resistance (Fig. 2*C* and Supplementary Fig.
152 S1*C*).
153
154 **Carbapenemase production and porin deficiency together cause a hyper-CRE phenotype.**
155 To directly test the hypothesis that the combination of carbapenemase production and porin
156 deficiency confers a hyper-CRE phenotype, we selected two clinical *Klebsiella pneumoniae*
157 isolates (BIDMC46a and BIDMC91) with disruptions in both major porins OmpK36 and
158 OmpK35, and transformed them with a pBAD33 plasmid encoding a KPC-3 (Fig. 3*A*). Both
159 transformants exhibited dramatic increases in MIC at standard inoculum (256-fold and 128-fold,
160 respectively) compared to empty vector controls and also developed an IE (6-fold from standard
161 to high inoculum). In a second experiment, we disrupted the major OmpK36 porin in a *K.*
162 *pneumoniae* isolate expressing a KPC-2 (RB582) using a CRISPR-Cas9 base editor (51).
163 Meropenem MICs at standard inoculum increased by 32-fold in the edited strain, with a small 2-
164 fold IE (Fig. 3*B*). These experiments provide direct evidence that the combination of
165 carbapenemase production and porin deficiency leads to a hyper-CRE phenotype.
166
167 **A significant proportion of carbapenemase-producing isolates change classification**
168 **within the CLSI inoculum range.** Although clinical microbiological laboratories initially
169 identified the isolates we studied as carbapenem-resistant, the IE caused the MIC of several
170 isolates to vary greatly within the CLSI inoculum range (Fig. 2*A*, and Supplementary Fig. S1*A*).
171 This variability prompted us to quantify which carbapenemase-producing isolates changed
172 susceptibility classification within the acceptable CLSI inoculum range of 2×10^5 CFU/mL to $8 \times$
173 10^5 CFU/mL. We tested both meropenem and ertapenem, two carbapenems in common clinical
174 use with distinct physicochemical and pharmacokinetic properties. Notably, ertapenem has a
175 lower barrier to resistance (52) since it is more affected by reduced outer membrane

176 permeability (53), and has lower clinical susceptibility breakpoints (22). 22 of 63 (35%)
177 carbapenemase-producing isolates tested with meropenem and 7 of 41 (17%) tested with
178 ertapenem changed AST classification (Fig. 4). When excluding hyper-CRE and considering
179 only isolates with intact porins, 18 of 36 (50%) CP-CRE isolates changed AST classification for
180 meropenem and 7 of 29 (24%) for ertapenem within the CLSI inoculum range. Concerningly,
181 three isolates changed from meropenem susceptible to resistant within the CLSI range (Fig. 4,
182 dotted lines), including one *E. coli* isolate (BIDMC43b) and two *Serratia marcescens* isolates
183 (BWH56 and BWH57), each of which encodes a KPC-3. Four isolates tested fully susceptible to
184 meropenem throughout the CLSI inoculum range (red circle), including two *Citrobacter freundii*
185 harboring KPC-3 (MGH281 and MGH283), and one *E. coli* (BAA2523) and one *K. pneumoniae*
186 (BAA2524) each harboring an OXA-48. In all, 15 of 63 (24%) carbapenemase producers (CP-
187 CRE or hyper-CRE) tested meropenem susceptible, and 2 of 41 (4.9%) tested ertapenem
188 susceptible, at some point in the CLSI inoculum range; this represented 15 of 36 (42%) and 2 of
189 29 (6.9%) CP-CRE, respectively.
190
191 **The inoculum effect accurately identifies carbapenemase production among CRE**. The
192 meropenem MIC at standard inoculum poorly distinguished carbapenemase-producing isolates
193 (CP-CRE or hyper-CRE) from PD-CRE (Fig. 5*A*), making it an inefficient metric to trigger
194 carbapenemase testing. By contrast, the clear phenotypic differences across inocula between
195 these groups led us to investigate a diagnostic approach based on the IE. We quantified the IE
196 by dividing the MIC at high inoculum (1.3×10^7 CFU/mL) by the MIC at standard inoculum ($4 \times$
197 10^5 CFU/mL) for each isolate (Fig. 5*B*). CRE exhibited distinct meropenem IEs depending on
198 their mechanism of resistance, with carbapenemase-producing isolates (CP-CRE and hyper-
199 CRE) exhibiting a much more prominent IE, with a median increase in MIC of 10-fold, compared
200 to a 1.2-fold increase for PD-CRE (Fig. 5*B*). To quantify binary classification distinguishing
201 carbapenemase-producing isolates from porin-deficient ones, we generated receiver operating

202 characteristic (ROC) curves using meropenem MIC (Fig. 5C) or IE (Fig. 5D) threshold values.
203 The area under each ROC curve (AUC) represents an aggregate measure of classification
204 accuracy in distinguishing isolates by resistance mechanism across all possible binary
205 thresholds of the metric being plotted. The meropenem IE distinguished carbapenemase-
206 producing CRE from PD-CRE better than meropenem MIC at standard inoculum, illustrated by a
207 ROC AUC of 0.99 for the meropenem IE versus 0.69 for meropenem MIC. To efficiently identify
208 CRE that might carry carbapenemases, precise IE threshold values can be chosen to optimize
209 sensitivity (detecting carbapenemases) while maintaining reasonable specificity. At one specific
210 IE threshold of 2.53-fold, the sensitivity and specificity of distinguishing carbapenemase-
211 encoding isolates from PD-CRE was 95.2% and 95.7%, respectively. The meropenem IE was
212 greater in CP-CRE (median 16-fold MIC increase) than hyper-CRE (median 5.3-fold), and it also
213 distinguished these two groups (Fig. 5 *B* and *D*; ROC AUC 0.89).
214
215 **Comparing ertapenem and meropenem MICs gives insights into resistance mechanisms.**
216 The meropenem IE effectively distinguished carbapenemase-producing isolates from PD-CRE,
217 but it is not a standard workflow in clinical laboratories, which typically only perform AST at
218 standard inocula. To overcome this limitation, since the periplasmic permeability of ertapenem is
219 typically more impacted by porin mutations than that of meropenem (6, 7, 44, 54), we
220 hypothesized that comparing ertapenem and meropenem MICs, even at a single inoculum,
221 might also distinguish CRE by mechanism of resistance. We thus measured ertapenem MICs
222 across a broad inoculum range for 85 of the 110 CRE isolates (Fig. 6). The ratio of ertapenem
223 MIC to meropenem MIC better separated carbapenemase producing isolates (CP-CRE or
224 hyper-CRE) from PD-CRE (Fig. 6*C*) than either the ertapenem or meropenem MIC alone (Fig. 6
225 *A* and *B*). At standard inoculum, meropenem MIC performed poorly at distinguishing
226 carbapenemase producers (CP-CRE or hyper-CRE) from PD-CRE (ROC AUC 0.559), whereas
227 ertapenem MIC performed slightly better (ROC AUC 0.696; Fig. 6*D*). By contrast, the

228 ertapenem-to-meropenem MIC ratio yielded a ROC AUC of 0.941, with a 90% sensitivity and
229 84% specificity at a ratio cutoff of 7.63 for detecting carbapenemase content. At low inoculum,
230 ertapenem MIC performed comparably to this ratio at identifying carbapenemase producing
231 isolates, while at high inoculum, meropenem MIC performed comparably. However, at the
232 standard CLSI inoculum, neither performed as well as the MIC ratio.
233
234 **Discussion**
235
236 Our systematic investigations revealed that the *in vitro* carbapenem inoculum effect (IE) is not
237 determined by the mechanism of action of the antibiotic, but rather by the mechanism of
238 resistance of the isolate. In *E. coli* K-12, we showed that expression of any carbapenemase is
239 sufficient to produce a carbapenem IE (Fig. 1). We confirmed this result in a collection of 110
240 clinical CRE isolates, where all CP-CRE exhibited a strong IE, whereas PD-CRE did not (Fig. 2,
241 Supplementary Fig. S1, and Table S3). Isolates with both mechanisms of resistance (hyper-
242 CRE) tended to have higher MICs and also exhibited an IE, although smaller in magnitude than
243 CP-CRE (Fig. 2*C* and Fig. 5*B*).
244 Our findings have important mechanistic, clinical, and diagnostic implications.
245 Mechanistically, all carbapenemases imparted a strong inoculum effect despite minimal
246 sequence or structural similarity across the four Ambler classes. Furthermore, we observed a
247 consistently biphasic dependence of CP-CRE MIC on inoculum (Fig. 1, Fig. 2 and
248 Supplementary Fig. S1): at the lowest inocula tested, carbapenemases conferred a relatively
249 constant degree of resistance, whereas above a certain threshold, resistance of the population
250 increased with cell density, by up to 100-fold at the highest cell densities compared with the
251 standard inoculum (Fig. 1B, Fig. 2A). This is consistent with a model where carbapenemases
252 provide cell-autonomous resistance at low density but increasing population-level resistance as
253 cell density increases, such that the collective production of carbapenemases may become the

254 dominant determinant of resistance at high enough cell density. Since the IE is only observed
255 with carbapenemase producers and not PD-CRE, one intriguing possibility is that
256 carbapenemases serve as a “common good” in bacterial populations above a certain density
257 threshold, as has been proposed for other secreted enzymes (36–38, 55). One recent study of
258 bacterial communities in which some members produced OXA-48 supports this model (40), but
259 further studies with mixed populations of carbapenemase producing and non-producing isolates
260 are needed to rigorously test this hypothesis. Notably, PD-CRE isolates expressing extended
261 spectrum β-lactamases (ESBLs), which often contribute to carbapenem resistance, did not
262 exhibit an appreciable carbapenem IE (Fig. 2*B* and Supplementary Fig. S1*B*), indicating that the
263 slow rates of carbapenem hydrolysis by ESBL enzymes were insufficient to benefit neighboring
264 bacteria even at high culture density. The lower prevalence of carbapenemases compared to
265 other β-lactamases may explain why the IE is reported less frequently for carbapenems than for
266 other β-lactams (56), but this might change as carbapenemases continue to spread globally.
267 The extent of and mechanistic basis for carbapenemase release into the extracellular space
268 where they may benefit neighboring cells, whether via secretion systems, outer membrane
269 vesicles, cell lysis, or other means, warrants more investigation.
270 The clinical implications of the inoculum effect have been uncertain because the relevant
271 bacterial cell densities during most infections *in vivo* are generally below those used for AST
272 (45, 55). For instance, in bacteremia, the infectious burden of ≤10 CFU/mL is several orders of
273 magnitude below that at which the inoculum begins to affect MIC in our assays (57, 58).
274 Nevertheless, in *Staphylococcus aureus* bacteremia, a cefazolin IE has been associated with
275 treatment failure and higher mortality (59, 60). Our findings suggest that at the low inoculum
276 present in bacteremia, PD-CRE (Fig. 2*B* and Supplementary Fig. S1*B*) exhibit higher
277 carbapenem MICs than CP-CRE (Fig. 2*A*, Fig. S1*A*), yet clinical outcomes are similar or worse
278 for CP-CRE bacteremia (61, 62). It is possible that the increased resistance of PD-CRE at
279 physiologically relevant bacterial densities may be offset by fitness costs associated with

280 reduced permeability. Further research is needed to fully understand the relationship between
281 MIC, IE, resistance mechanisms, and clinical outcomes. Intriguing recent studies found that
282 isolates encoding carbapenemases and displaying a large inoculum effect require higher
283 meropenem concentration to prevent emergence of highly resistant mutants (39, 52). Since we
284 observed the largest IE among CP-CRE with intact porins, perhaps these extremely resistant
285 escape mutants reflect *de novo* porin mutations, creating hyper-CRE.

286 Diagnostically, accurate recognition of carbapenem resistance is crucial for infection
287 control strategies and patient care. Our results confirmed prior reports that minor differences in
288 inoculum can lead to categorical changes in susceptibility interpretation (45), particularly
289 impacting the detection of CP-CRE, the isolates that carry the greatest implications for infection
290 control. Even though the isolates we examined were selected because they tested as CRE,
291 many changed classification within the CLSI-acceptable inoculum range and even appeared
292 susceptible (Fig. 4), suggesting that clinical algorithms may miss some isolates encoding
293 carbapenemases. In fact, MICs of all CP-CRE isolates varied significantly in this range. Our
294 observations in *E. coli* K-12 (Fig. 1) reveal that strains harboring OXA-48, CMY-10, or even KPC
295 might only test resistant if they possess other factors, such as reduced antibiotic permeability.
296 The clinical significance of isolates that express a carbapenemase but test susceptible in the
297 standard inoculum range is uncertain and requires further study. Nonetheless, caution is
298 generally advised when using carbapenems in infections with carbapenemase-producers, even
299 if they test susceptible, due to the lack of evidence supporting clinical outcomes in these cases
300 (22). Our findings in a set of isolates selected for meropenem nonsusceptibility suggest that
301 other carbapenemase producers may have been missed by standard diagnostic workflows,
302 which could contribute to poor patient outcomes and the global spread of carbapenem
303 resistance.

304 The strong correlation between the carbapenem IE and genotype (Fig. 2) allows for
305 improved predictions about resistance mechanisms from phenotypic testing. Although MICs

306 were not designed to identify resistance mechanisms, carbapenem MICs are routinely used to
307 prioritize isolates for molecular carbapenemase testing (63), though different MIC thresholds for
308 testing are recommended in the US (22) and Europe (26). Our study revealed that the
309 meropenem IE is a more sensitive and specific indicator of carbapenemase production in CRE
310 than MIC at any single inoculum (Fig. 5). Although measuring the meropenem IE would require
311 additional testing workflows, we also found that integrating ertapenem and meropenem MICs
312 from routinely generated AST data can inform the likelihood of carbapenemase production (Fig.
313 6). The ratio of ertapenem to meropenem MIC predicts resistance mechanism better than either
314 MIC alone, perhaps because the periplasmic permeability of ertapenem is more strongly
315 affected by porin disruption than that of meropenem (6, 44, 54), while both are hydrolyzed at
316 similar rates by carbapenemases (64, 65). Predicting porin function has been a major challenge
317 for genomic resistance prediction (66–71), as polymorphisms are frequently found but
318 challenging to functionally interpret. Given the differential impact of porin mutations on each
319 carbapenem, the ertapenem-to-meropenem MIC ratio may offer a phenotypic reflection of porin
320 function. Specifically, CRE with a high ratio of ertapenem to meropenem MIC (more resistant to
321 ertapenem) are likely to be PD-CRE, whereas those with a low MIC ratio (similar resistance to
322 both) are likely to be CP-CRE. As with the inoculum effect, hyper-CRE appear to fall in between,
323 and tend to have higher MICs at any inoculum. Since the IE impacts both ertapenem and
324 meropenem MICs similarly (Fig. 4), this ratio predicts resistance mechanism independent of
325 inoculum, an advantage over either ertapenem or meropenem MICs alone (Fig. 6).
326 We propose that this ertapenem to meropenem MIC ratio might therefore be better
327 suited than either MIC alone to inform downstream testing and prioritize isolates for molecular or
328 enzymatic carbapenemase detection (19, 72, 73). Recognizing that MIC thresholds for
329 susceptibility may miss carbapenemase-producing isolates, EUCAST recommends a 16-fold
330 lower MIC threshold for carbapenemase screening than their clinical susceptibility breakpoint
331 (26). This lower threshold will lead to more sensitive carbapenemase detection, but at lower

332 specificity, requiring far more testing. If validated in further studies at this lower MIC threshold,
333 the ertapenem to meropenem MIC ratio may enable optimization of strain selection for
334 molecular carbapenemase testing. By more efficiently identifying carbapenemase-producing
335 isolates, our work could facilitate implementation of recent advances showing that molecular
336 detection of carbapenemases can accelerate administration of targeted therapies, such as β-
337 lactamase inhibitor combinations (74), and decrease mortality (21). Moreover, this phenotypic
338 approach could detect strains producing rare carbapenemases, such as SME or CMY-10, that
339 are not routinely included in testing panels, akin to the Carba NP (22, 75) and mCIM methods
340 (20). This finding, in addition to its therapeutic value, could serve as a surveillance tool for the
341 emergence and evolution of carbapenemases (76). This work does not aim to replace well-
342 validated clinical carbapenemase detection methods. Instead, it illustrates how biological
343 phenomena can offer further insights into resistance mechanism in a clinical context.
344 This study has several limitations and areas requiring further study. First, the clinical
345 isolates analyzed were mostly chosen because they tested carbapenem resistant, limiting the
346 ability to determine the frequency of CP-CRE isolates that may be missed by routine testing due
347 to the IE. Further studies are needed to assess the performance of our proposed assays on
348 isolates with MICs at or below the susceptible breakpoint. Second, automated AST instruments
349 may not provide precise MIC measurements for ertapenem and meropenem outside a narrow
350 range around the susceptibility breakpoints, requiring further investigation into the utility of these
351 lower-resolution MIC estimates in screening for CP-CRE. Third, while we found
352 carbapenemases sufficient to confer a carbapenem IE, other factors such as heteroresistance,
353 metabolic factors, quorum sensing, and target distribution may also contribute in some isolates
354 or circumstances. However, carbapenemases predictably cause a robust IE without requiring
355 other factors. Our findings reveal a clear pattern: as the inoculum increases above a certain
356 threshold, we observe a steady linear rise in MIC (Fig. 2 and Supplementary Fig. S1). This
357 pattern is less consistent with heteroresistance, an alternative explanation for the IE whereby a

358 rare resistant subpopulation emerges from larger inocula. With heteroresistance, one would
359 expect a sudden step-like increase in MIC as inoculum rises, as opposed to the gradual MIC
360 increase that we consistently observed. Lastly, this study did not explore the basis of the IE for
361 other antibiotics, nor how other processes like antibiotic efflux may contribute to carbapenem
362 resistance. However, the consistent relationship between resistance mechanism and the IE for
363 carbapenems, where hydrolytic enzymes and other resistance mechanisms are relatively few
364 and well characterized, may offer a useful general model for one major mechanism underlying
365 the IE. Future studies could involve pairing these detailed phenotypic data and genotypic
366 information (*SI Appendix*, Table S3) with precise enzymological parameters and direct
367 quantification of enzymes and metabolites in different compartments in order to enhance and
368 experimentally test existing quantitative models (37, 55). This would enable a more
369 comprehensive description of how different mechanisms of antibiotic resistance impact the
370 growth of bacterial populations when exposed to antibiotic selection.
371
372 **Methods:**
373
374 **Bacterial isolates.** The use and collection of bacterial strains from three major Boston-area
375 hospitals (Beth Israel Deaconess Medical Center, BIDMC; Brigham and Women's Hospital,
376 BWH; Massachusetts General Hospital, MGH) was approved by the Partners Health Care
377 Institutional Review Board (IRB under protocol 2015P002215) and additional IRB approval was
378 granted by the Massachusetts Institute of Technology Committee on the Use of Humans as
379 Experimental Subjects. Additional isolates were acquired through the University of California
380 Irvine School of Medicine (UCI), the Wadsworth Center of the New York State Department of
381 Health (NYSDOH), the FDA-CDC Antimicrobial Resistance Isolate Bank (CDC, Atlanta, GA),
382 and the American Type Culture Collection (ATCC) (Manassas, VA).
383

384 **Cloning of carbapenemases**. *bla*$_{KPC-3}$, *bla*$_{SME-2}$, *bla*$_{IMP-4}$, *bla*$_{NDM-1}$, *bla*$_{VIM-27}$, and *bla*$_{OXA-48}$ along
385 with their native promoters were cloned by Gibson assembly from isolates in our existing CRE
386 collection (11, 12) encoding these carbapenemases into a pBAD33 plasmid which encodes
387 chloramphenicol resistance (*SI Appendix*, Table S1). *bla*$_{CMY-10}$ with its native promoter was
388 synthesized in the same pBAD33 vector backbone by GeneWiz (Suzhou, China), since we did
389 not have a clinical isolate expressing this enzyme.
390
391 **Broad-range broth microdilution.** Our MIC assays were adapted from previously published
392 broth microdilution methods(24, 77). See Supplemental Methods for details on setup of the
393 broad inoculum range in this assay format.
394
395 **Data analysis.** MIC replicates were imported to GraphPad Prism v 9.5.1 (GraphPad Software
396 Inc., San Diego, CA); MIC vs inoculum plots (Figs. 1, 2, and 3, and Supplementary Fig. S1)
397 depict mean and standard errors of the mean. To analyze the meropenem IE, the ratio of mean
398 MIC at 1.3×10^7 CFU/mL to 4×10^5 CFU/mL was calculated. The IE of the 47 porin deficient
399 CRE strains were compared to the 63 carbapenemase-encoding CRE strains using a non-
400 parametric test (Mann-Whitney for comparisons between two groups or Kruskal-Wallis for
401 analysis of more than two groups) in GraphPad Prism. Statistical analysis comparing PD-CRE
402 isolates versus CP-CRE and hyper-CRE isolate at low, standard, and high inocula for
403 ertapenem, meropenem, and ertapenem-to-meropenem MIC ratio was conducted using Mann-
404 Whitney tests. All receiver operating characteristic (ROC) curves and analysis were constructed
405 using GraphPad Prism.
406
407 **Gene editing to disrupt OmpK36 in *Klebsiella pneumoniae* isolate RB582.** A CRISPR-Cas9
408 cytidine base-editing system(51) was used to introduce an early termination codon in the intact
409 *ompK36* of isolate RB582. See Supplemental Methods for further details.

Acknowledgements

We thank Pierre O. Ankomah, Jonathan Chen, Alyssa DuBois, Alasdair Fletcher, James E. Gomez, Ria Kolli, Jonathan Livny, Peijun Ma, Melanie A. Martinsen, Michelle E. Matzko, David J. Roach, and Eleanor L. Young for helpful advice.

We thank Kimberly Musser, the Wadsworth Center, and the CDC ARBank for sharing isolates.

This work was supported in part by the Broad Institute Next Generation Fund (RPB) and federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Grant Number U19AI110818 to the Broad Institute.

References:

1. M. I. El-Gamal, *et al.*, Recent updates of carbapenem antibiotics. *Eur. J. Med. Chem.* **131**, 185–195 (2017).
2. F. S. Codjoe, E. S. Donkor, Carbapenem Resistance: A Review. *Med. Sci.* **6** (2018).
3. CDC, Antibiotic resistance threats in the United States. *Centers Dis. Control Prev.*, 1–113 (2019).
4. E. S. Snitkin, *et al.*, Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. *Sci. Transl. Med.* **4**, 148ra116 (2012).
5. K. Bush, P. A. Bradford, Epidemiology of β-Lactamase-Producing Pathogens. *Clin. Microbiol. Rev.* **33** (2020).
6. A. Rocker, *et al.*, Global Trends in Proteome Remodeling of the Outer Membrane Modulate Antimicrobial Permeability in Klebsiella pneumoniae. *MBio* **11** (2020).
7. S. Acosta-Gutiérrez, *et al.*, Getting Drugs into Gram-Negative Bacteria: Rational Rules for Permeation through General Porins. *ACS Infect. Dis.* **4**, 1487–1498 (2018).
8. Y. Zhang, *et al.*, Overproduction of efflux pumps caused reduced susceptibility to carbapenem under consecutive imipenem-selected stress in Acinetobacter baumannii. *Infect. Drug Resist.* **11**, 457–467 (2018).
9. H. Pai, *et al.*, Carbapenem Resistance Mechanisms in Pseudomonas aeruginosa Clinical Isolates. *Antimicrob. Agents Chemother.* **45**, 480–484 (2001).
10. M. J. Schwaber, *et al.*, Containment of a Country-wide Outbreak of Carbapenem-Resistant Klebsiella pneumoniae in Israeli Hospitals via a Nationally Implemented Intervention. *Clin. Infect. Dis.* **52**, 848–855 (2011).
11. R. Salamzade, *et al.*, Inter-species geographic signatures for tracing horizontal gene transfer and long-term persistence of carbapenem resistance. *Genome Med.* **14** (2022).
12. G. C. Cerqueira, *et al.*, Multi-institute analysis of carbapenem resistance reveals remarkable diversity, unexplained mechanisms, and limited clonal outbreaks. *Proc. Natl. Acad. Sci. United States gof Am.* **114**, 1135–1140 (2017).
13. A. J. Mathers, *et al.*, Molecular dissection of an outbreak of carbapenem-resistant Enterobacteriaceae reveals intergenus KPC carbapenemase transmission through a promiscuous plasmid. *MBio* **2** (2011).
14. U. Choi, C.-R. R. Lee, Distinct Roles of Outer Membrane Porins in Antibiotic Resistance and Membrane Integrity in Escherichia coli. *Front. Microbiol.* **0**, 953 (2019).
15. A. Alva, A. Sabido-Ramos, A. Escalante, F. Bolívar, New insights into transport capability of sugars and its impact on growth from novel mutants of Escherichia coli. *Appl. Microbiol. Biotechnol.* **104**, 1463–1479 (2020).
16. J. Andersen, S. A. Forst, K. Zhao, M. Inouye, N. Delihas, The function of micF RNA: micF RNA is a major factor in the thermal regulation of OmpF protein in Escherichia coli. *J. Biol. Chem.* **264**, 17961–17970 (1989).
17. J. Abellón-Ruiz, *et al.*, Structural basis for maintenance of bacterial outer membrane lipid asymmetry. *Nat. Microbiol.* **2**, 1616–1623 (2017).
18. K. E. Goodman, P. J. Simner, P. D. Tamma, A. M. Milstone, Infection control implications of heterogeneous resistance mechanisms in carbapenem-resistant Enterobacteriaceae (CRE). *Expert Rev. Anti. Infect. Ther.* **14**, 95–108 (2016).
19. D. Gu, *et al.*, Comparison of the NG-Test Carba 5, Colloidal Gold Immunoassay (CGI) Test, and Xpert Carba-R for the Rapid Detection of Carbapenemases in Carbapenemase-Producing Organisms. *Antibiotics* **12**, 300 (2023).
20. V. M. Pierce, *et al.*, Modified carbapenem inactivation method for phenotypic detection of carbapenemase production among enterobacteriaceae. *J. Clin. Microbiol.* **55**, 2321–2333 (2017).

21. M. J. Satlin, *et al.*, Impact of a Rapid Molecular Test for Klebsiella pneumoniae Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem-Resistant Enterobacterales. *Clin. Infect. Dis.* **75**, 2066–2075 (2022).
22. Clinical and Laboratory Standards Institute, *M100 Performance Standards for Antimicrobial Susceptibility Testing* (2023) (May 2, 2023).
23. M. P. Weinstein, J. S. Lewis, The clinical and laboratory standards institute subcommittee on Antimicrobial susceptibility testing: Background, organization, functions, and processes. *J. Clin. Microbiol.* **58** (2020).
24. Clinical and Laboratory Standards Institute, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition. CLSI document M07-A10. Wayne, PA: Clinical and Laboratory Standards Institute. *Clin. Lab. Stand. Inst.* (2015).
25. R. M. Humphries, *et al.*, Carbapenem-Resistant Enterobacteriaceae Detection Practices in California: What Are We Missing? *Clin. Infect. Dis.* **66**, 1061–1067 (2018).
26. EUCAST, The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 13.0, 2023. http://www.eucast.org.". *http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_5.0_Breakpoint_Table_01.pdf* (2023).
27. R. M. Humphries, A. N. Abbott, J. A. Hindler, Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories. *J. Clin. Microbiol.* **57** (2019).
28. P. Nordmann, *et al.*, Identification and screening of carbapenemase-producing Enterobacteriaceae. *Clin. Microbiol. Infect.* **18**, 432–438 (2012).
29. A. Adler, M. Ben-Dalak, I. Chmelnitsky, Y. Carmeli, Effect of Resistance Mechanisms on the Inoculum Effect of Carbapenem in Klebsiella pneumoniae Isolates with Borderline Carbapenem Resistance. **59** (2015).
30. I. Brook, Inoculum Effect. *Rev. Infect. Dis.* **11**, 361–368 (1989).
31. A. Gutierrez, *et al.*, Understanding and Sensitizing Density-Dependent Persistence to Quinolone Antibiotics. *Mol. Cell* **68**, 1147-1154.e3 (2017).
32. G. Diaz-Tang, *et al.*, Growth productivity as a determinant of the inoculum effect for bactericidal antibiotics. *Sci. Adv.* **8** (2022).
33. K. I. Udekwu, N. Parrish, P. Ankomah, F. Baquero, B. R. Levin, Functional relationship between bacterial cell density and the efficacy of antibiotics. *J. Antimicrob. Chemother.* **63**, 745–757 (2009).
34. O. Scheler, *et al.*, Droplet-based digital antibiotic susceptibility screen reveals single-cell clonal heteroresistance in an isogenic bacterial population. *Sci. Rep.* **10**, 1–8 (2020).
35. C. Tan, *et al.*, The inoculum effect and band-pass bacterial response to periodic antibiotic treatment. *Mol. Syst. Biol.* **8** (2012).
36. L. A. Dugatkin, M. Perlin, J. S. Lucas, R. Atlas, Group-beneficial traits, frequency-dependent selection and genotypic diversity: an antibiotic resistance paradigm. *Proc. R. Soc. B Biol. Sci.* **272**, 79–83 (2005).
37. N. M. Vega, J. Gore, Collective antibiotic resistance: mechanisms and implications. *Curr. Opin. Microbiol.* **21**, 28–34 (2014).
38. L. Geyrhofer, *et al.*, Minimal Surviving Inoculum in Collective Antibiotic Resistance. *MBio* (2023) https:/doi.org/10.1128/MBIO.02456-22 (April 24, 2023).
39. M. V. Golikova, *et al.*, Meropenem MICs at Standard and High Inocula and Mutant Prevention Concentration Inter-Relations: Comparative Study with Non-Carbapenemase-Producing and OXA-48-, KPC- and NDM-Producing Klebsiella pneumoniae. *Antibiot. (Basel, Switzerland)* **12** (2023).
40. A. Pathak, D. C. Angst, R. León-Sampedro, A. R. Hall, Antibiotic-degrading resistance changes bacterial community structure via species-specific responses. *ISME J.* **17**

523 (2023).
524 41. R. H. K. Eng, C. Cherubin, S. M. Smith, F. Buccini, Inoculum effect of β-lactam antibiotics
525 on Enterobacteriaceae. *Antimicrob. Agents Chemother.* **28**, 601–606 (1985).
526 42. Y. Harada, *et al.*, In vitro and in vivo activities of piperacillin-tazobactam and meropenem
527 at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. *Clin. Microbiol.*
528 *Infect.* **20**, O831–O839 (2014).
529 43. D. G. Lee, Y. Murakami, D. R. Andes, W. A. Craig, Inoculum Effects of Ceftobiprole,
530 Daptomycin, Linezolid, and Vancomycin with Staphylococcus aureus and Streptococcus
531 pneumoniae at Inocula of 105 and 107 CFU Injected into Opposite Thighs of Neutropenic
532 Mice. *Antimicrob. Agents Chemother.* **57**, 1434 (2013).
533 44. M. Doumith, M. J. Ellington, D. M. Livermore, N. Woodford, Molecular mechanisms
534 disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp.
535 clinical isolates from the UK. *J. Antimicrob. Chemother.* **63**, 659–667 (2009).
536 45. K. P. Smith, J. E. Kirby, The inoculum effect in the era of multidrug resistance: Minor
537 differences in inoculum have dramatic effect on MIC Determination. *Antimicrob. Agents*
538 *Chemother.* **62**, 1–9 (2018).
539 46. J. D. Lutgring, *et al.*, FDA-CDC Antimicrobial Resistance Isolate Bank: a Publicly
540 Available Resource To Support Research, Development, and Regulatory Requirements.
541 *J. Clin. Microbiol.* **56** (2018).
542 47. R. P. Ambler, "The structure of β-lactamases" (1980).
543 48. T. Sawa, K. Kooguchi, K. Moriyama, Molecular diversity of extended-spectrum β-
544 lactamases and carbapenemases, and antimicrobial resistance (J Intensive Care, 2020).
545 49. L. M. Guzman, D. Belin, M. J. Carson, J. Beckwith, Tight regulation, modulation, and
546 high-level expression by vectors containing the arabinose P(BAD) promoter. *J. Bacteriol.*
547 **177**, 4121–4130 (1995).
548 50. J. Y. Kim, *et al.*, Structural basis for the extended substrate spectrum of CMY-10, a
549 plasmid-encoded class C β-lactamase. *Mol. Microbiol.* **60**, 907–916 (2006).
550 51. Y. Wang, *et al.*, CRISPRCas9 and CRISPR-assisted cytidine deaminase enable precise
551 and efficient genome editing in Klebsiella pneumoniae. *Appl. Environ. Microbiol.* **84**
552 (2018).
553 52. P. Ma, *et al.*, Genetic determinants facilitating the evolution of resistance to carbapenem
554 antibiotics. *Elife* **10** (2021).
555 53. M. W. Adelman, *et al.*, Distinctive Features of Ertapenem-Mono-Resistant Carbapenem-
556 Resistant Enterobacterales in the United States: A Cohort Study. *Open Forum Infect. Dis.*
557 **9** (2022).
558 54. Y. K. Tsai, C. H. Liou, C. P. Fung, J. C. Lin, L. K. Siu, Single or in Combination
559 Antimicrobial Resistance Mechanisms of Klebsiella pneumoniae Contribute to Varied
560 Susceptibility to Different Carbapenems. *PLoS One* **8**, e79640 (2013).
561 55. T. Artemova, Y. Gerardin, C. Dudley, N. M. Vega, J. Gore, Isolated cell behavior drives
562 the evolution of antibiotic resistance. *Mol. Syst. Biol.* **11**, 822 (2015).
563 56. J. R. Lenhard, Z. P. Bulman, Inoculum effect of β-lactam antibiotics. *J. Antimicrob.*
564 *Chemother.* **74**, 2825–2843 (2019).
565 57. O. Opota, A. Croxatto, G. Prod'hom, G. Greub, Blood culture-based diagnosis of
566 bacteraemia: state of the art. *Clin. Microbiol. Infect.* **21**, 313–322 (2015).
567 58. C. Zhang, *et al.*, Identification of low abundance microbiome in clinical samples using
568 whole genome sequencing. *Genome Biol.* **16** (2015).
569 59. W. R. Miller, *et al.*, The Cefazolin Inoculum Effect Is Associated With Increased Mortality
570 in Methicillin-Susceptible Staphylococcus aureus Bacteremia. *Open forum Infect. Dis.* **5**
571 (2018).
572 60. E. C. Nannini, *et al.*, Inoculum effect with cefazolin among clinical isolates of methicillin-
573 susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment

failure. *Antimicrob. Agents Chemother.* **53**, 3437–3441 (2009).
61. P. D. Tamma, *et al.*, Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase- producing carbapenem-resistant enterobacteriaceae bacteremia. *Clin. Infect. Dis.* **64**, 257–264 (2017).
62. M. R. Hovan, N. Narayanan, V. Cedarbaum, T. Bhowmick, T. J. Kirn, Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia. *Diagn. Microbiol. Infect. Dis.* **101** (2021).
63. S. S. Jean, W. Sen Lee, P. R. Hsueh, Ertapenem non-susceptibility and independent predictors of the carbapenemase production among the Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). *Infect. Drug Resist.* **11**, 1881 (2018).
64. N. K. Stewart, C. A. Smith, H. Frase, D. J. Black, S. B. Vakulenko, Kinetic and Structural Requirements for CarbapenemaseActivity in GES-Type β-Lactamases. *Biochemistry* **54**, 588 (2015).
65. T. L. Lamoureaux, H. Frase, N. T. Antunes, S. B. Vakulenko, Antibiotic Resistance and Substrate Profiles of the Class A Carbapenemase KPC-6. *Antimicrob. Agents Chemother.* **56**, 6006–6008 (2012).
66. M. W. Pesesky, *et al.*, Evaluation of Machine Learning and Rules-Based Approaches for Predicting Antimicrobial Resistance Profiles in Gram-negative Bacilli from Whole Genome Sequence Data. *Front. Microbiol.* **7** (2016).
67. B. B. Flury, *et al.*, Association of Novel Nonsynonymous Single Nucleotide Polymorphisms in ampD with Cephalosporin Resistance and Phylogenetic Variations in ampC, ampR, ompF, and ompC in Enterobacter cloacae Isolates That Are Highly Resistant to Carbapenems. *Antimicrob. Agents Chemother.* **60**, 2383–2390 (2016).
68. S. A. Shelburne, *et al.*, Whole-Genome Sequencing Accurately Identifies Resistance to Extended-Spectrum β-Lactams for Major Gram-Negative Bacterial Pathogens. *Clin. Infect. Dis.* **65**, 738–745 (2017).
69. D. E. Foudraine, *et al.*, Exploring antimicrobial resistance to beta-lactams, aminoglycosides and fluoroquinolones in E. coli and K. pneumoniae using proteogenomics. *Sci. Rep.* **11** (2021).
70. C. S. Suelter, N. D. Hanson, OmpC regulation differs between ST131 and non-ST131 Escherichia coli clinical isolates and involves differential expression of the small RNA MicC. *J. Antimicrob. Chemother.* **75**, 1151–1158 (2020).
71. J. L. C. Wong, *et al.*, Recurrent emergence of Klebsiella pneumoniae carbapenem resistance mediated by an inhibitory ompK36 mRNA secondary structure. *Proc. Natl. Acad. Sci. U. S. A.* **119**, e2203593119 (2022).
72. J. Monteiro, R. H. Widen, A. C. C. Pignatari, C. Kubasek, S. Silbert, Rapid detection of carbapenemase genes by multiplex real-time PCR. *J. Antimicrob. Chemother.* **67**, 906–909 (2012).
73. P. D. Tamma, P. J. Simner, Phenotypic detection of carbapenemase-producing organisms from clinical isolates. *J. Clin. Microbiol.* **56** (2018).
74. J. C. Vázquez-Ucha, J. Arca-Suárez, G. Bou, A. Beceiro, New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams. *Int. J. Mol. Sci.* **21**, 9308 (2020).
75. B. Elawady, M. Ghobashy, A. Balbaa, Rapidec Carba NP for Detection of Carbapenemase-Producing Enterobacteriaceae in Clinical Isolates: A Cross-Sectional Study. *Surg. Infect. (Larchmt).* **20**, 672–676 (2019).
76. R. C. MacLean, A. S. Millan, The evolution of antibiotic resistance. *Science (80-.).* **365**, 1082–1083 (2019).
77. I. Wiegand, K. Hilpert, R. E. W. Hancock, Agar and broth dilution methods to determine

625 the minimal inhibitory concentration (MIC) of antimicrobial substances. *Nat. Protoc.* **3**,
626 163–175 (2008).
627

Figures



Fig. 1. All carbapenemases impart a meropenem inoculum effect when expressed in *E. coli K12*. (A) Plots of optical density (OD) at 600 nm (y-axis) after overnight incubation with varying meropenem concentrations (x-axis) across a broad range of starting inocula (grayscale per top right panel) for *E. coli* K-12 transformed with each indicated carbapenemase. **(B)** Meropenem minimum inhibitory concentration (MIC) as a function of bacterial inoculum, colored by transformed carbapenemase. Each MIC point is the mean of three replicates (error bars = standard error of the mean). Vertical dotted lines represent the CLSI-acceptable inoculum range (2 to 8 x 10^5 CFU/mL). The background is shaded by CLSI meropenem susceptibility breakpoints (S = susceptible, white; I = intermediate, light gray; R = resistant, gray).



Fig. 2. Select CRE exhibit different patterns of carbapenem inoculum effect depending on resistance mechanism. Meropenem MICs from broth microdilution assays (y-axis) across a broad range of starting inocula (x-axis) of select clinical CRE isolates encoding **(A)** a carbapenemase of each major type, **(B)** porin deficiency, or **(C)** both, with species and relevant genotype as indicated. One susceptible isolate (MGH19, gray) is also shown in panel **(A)**. Each MIC point is the mean of three replicates (error bars = standard error of the mean). *C spp* = *Citrobacter* spp, *Ecl* = *Enterobacter cloacae*, *Eco* = *Escherichia coli*, *Kae* = *Klebsiella aerogenes*, *Kpn* = *Klebsiella pneumoniae*, *Kqu* = *Klebsiella quaispneumoniae*, *Sma* = *Serratia marcescens*. CPase = carbapenemase. Vertical dotted lines reflect the CLSI-recommended inoculum range, background shading reflects CLSI breakpoints, and line color reflects carbapenemase content, all as in Fig. 1; dashed lines indicate porin deficiency.



Fig. 3. Carbapenemase production and porin deficiency together create a hyper-CRE phenotype. Broad-range meropenem broth microdilution assays for **(A)** two clinical PD-CRE isolates before and after transformation with pBAD33_KPC-3 and **(B)** a clinical CP-CRE isolate and three derivative colonies in which OmpK36 was disrupted by CRISPR-Cas9 based gene editing to create a premature stop at one of two glutamines as indicated. The parental KPC-expressing isolate (RB582) is shown as a solid line with green markers. Each MIC point is the mean of three replicates (error bars = standard error of the mean). Vertical dotted lines reflect the CLSI-recommended inoculum range, background shading reflects CLSI breakpoints, and line color reflects carbapenemase content as in Fig. 1; dashed lines indicate porin deficiency as in Fig. 2. *Kpn = Klebsiella pneumoniae.*



Fig 4. Many carbapenemase-producing isolates change AST classification in the CLSI range. Broad-range broth microdilution assays for **(A)** 63 carbapenemase-producing clinical CRE isolates (36 CP-CRE and 27 hyper-CRE) treated with meropenem and **(B)** 41 carbapenemase-producing clinical CRE isolates (30 CP-CRE and 11 hyper-CRE) treated with ertapenem. Each MIC measurement was the mean of three replicates. Error bars were omitted for simplicity. Isolates that tested anything other than resistant at some point in the CLSI-recommended inoculum range are colored by carbapenemase content; those that tested resistant throughout the CLSI range are in gray. Inset table shows the number and percentage of isolates by AST class across the CLSI inoculum range; red text indicates isolates that tested susceptible at some point within the CLSI range. Four CP-CRE that tested fully meropenem-susceptible throughout the CLSI range are indicated with a red circle. Isolates whose meropenem susceptibility category changed from susceptible to resistant in the CLSI range are shown as dotted lines.



Fig. 5. Meropenem inoculum effect robustly classifies CRE isolates by resistance mechanism. (A) Meropenem MICs for 110 CRE grouped by genotypic mechanism of carbapenem resistance: CP-CRE (circles), PD-CRE (triangles), or hyper-CRE (squares). Isolates are colored by carbapenemase content as in Fig. 1. Each MIC point is the mean of three replicates. **(B)** Ratio of meropenem MIC at high (1.3 x 10^7 CFU/mL) versus standard (4.0 x 10^5 CFU/mL) inoculum for 110 CRE, grouped as in **(A).** P-values were obtained by conducting statistical analyses on the three groups in **(A)** and **(B)** using a Kruskal-Wallis test. **(C)** Receiver operating characteristic (ROC) curves based on the meropenem MICs at standard inoculum from **(A)** comparing the different genotypic CRE groups. Inset tabulates each ROC area under the curve (AUC), sensitivity (Se), and specificity (Sp) at an optimal cutoff (OC) threshold, indicated by the red points on the ROC curves. **(D)** ROC curves based on the meropenem inoculum effect, displayed as in **(C)**. Any CPase = either CP-CRE or hyper-CRE.



Fig. 6. Comparing ertapenem and meropenem MICs gives insight into resistance mechanism (A-C) MICs of ertapenem **(A)** or meropenem **(B)**, or the ratio of the ertapenem MIC to the meropenem MIC **(C),** are shown for 85 isolates at low, standard, and high inoculum (left, middle, and right panels respectively), grouped

by resistance mechanism along the x-axis (hyper-CRE = “Hy-CRE”). Data points are colored based on carbapenemase content as in Fig. 1. Plot backgrounds are shaded by CLSI breakpoints for ertapenem **(A**) or meropenem **(B**) as in Fig. 1. P-values were obtained by conducting statistical analyses on the three groups in using a Kruskal-Wallis test. In chemical structures, the carbapenem core is red and the modifiable substituents are black. **(D)** ROC curves comparing carbapenemase producers (CP-CRE + hyper-CRE) vs PD-CRE for each metric (red = ertapenem MIC, blue = meropenem MIC, purple = MIC ratio) at low, standard, and high inoculum. Inset tabulates ROC AUC and sensitivity (Se) and specificity (Sp) at an optimal cutoff (OC, indicated by arrow on ROC curve).